Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Scheltema MJ"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-10 z 10
    Tytuł:
    Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial.
    Autorzy:
    Scheltema MJ; Department of Urology, AMC University Hospital, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. m.j.scheltema@amc.nl.
    van den Bos W; Department of Urology, AMC University Hospital, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
    de Bruin DM; Department of Urology, AMC University Hospital, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.; Department of Biomedical Engineering and Physics, AMC University Hospital, Amsterdam, The Netherlands.
    Wijkstra H; Department of Urology, AMC University Hospital, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.; Signal Processing Systems, Eindhoven University of Technology, Eindhoven, The Netherlands.
    Laguna MP; Department of Urology, AMC University Hospital, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
    de Reijke TM; Department of Urology, AMC University Hospital, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
    de la Rosette JJ; Department of Urology, AMC University Hospital, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
    Pokaż więcej
    Źródło:
    BMC cancer [BMC Cancer] 2016 May 05; Vol. 16, pp. 299. Date of Electronic Publication: 2016 May 05.
    Typ publikacji:
    Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Ablation Techniques/*methods
    Electroporation/*methods
    Prostatic Neoplasms/*therapy
    Ablation Techniques/adverse effects ; Adult ; Aged ; Biopsy ; Humans ; Male ; Middle Aged ; Neoplasm Grading ; Prostate/pathology ; Prostatic Neoplasms/pathology ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer.
    Autorzy:
    Scheltema MJ; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
    van den Bos W; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
    Siriwardana AR; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
    Kalsbeek AMF; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
    Thompson JE; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
    Ting F; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
    Böhm M; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
    Haynes AM; Garvan Institute of Medical Research and Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
    Shnier R; Southern Radiology, Randwick, NSW, Australia.
    Delprado W; Douglass Hanly Moir Pathology, Macquarie Park, NSW, Australia.
    Stricker PD; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
    Pokaż więcej
    Źródło:
    BJU international [BJU Int] 2017 Nov; Vol. 120 Suppl 3, pp. 51-58. Date of Electronic Publication: 2017 Sep 19.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Ablation Techniques/*adverse effects
    Ablation Techniques/*methods
    Neoplasm Recurrence, Local/*therapy
    Prostatic Neoplasms/*therapy
    Salvage Therapy/*adverse effects
    Salvage Therapy/*methods
    Aged ; Feasibility Studies ; Humans ; Male ; Neoplasm Recurrence, Local/epidemiology ; Prostatic Neoplasms/epidemiology ; Quality of Life ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Focal irreversible electroporation as primary treatment for localized prostate cancer.
    Autorzy:
    van den Bos W; Garvan Institute of Medical Research and Kinghorn Cancer Centre.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
    Scheltema MJ; Garvan Institute of Medical Research and Kinghorn Cancer Centre.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
    Siriwardana AR; Garvan Institute of Medical Research and Kinghorn Cancer Centre.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
    Kalsbeek AMF; Garvan Institute of Medical Research and Kinghorn Cancer Centre.
    Thompson JE; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
    Ting F; Garvan Institute of Medical Research and Kinghorn Cancer Centre.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
    Böhm M; Garvan Institute of Medical Research and Kinghorn Cancer Centre.
    Haynes AM; Garvan Institute of Medical Research and Kinghorn Cancer Centre.
    Shnier R; Southern Radiology, Randwick.
    Delprado W; Douglass Hanly Moir Pathology, Macquarie Park, NSW, Australia.
    Stricker PD; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
    Pokaż więcej
    Źródło:
    BJU international [BJU Int] 2018 May; Vol. 121 (5), pp. 716-724. Date of Electronic Publication: 2017 Sep 04.
    Typ publikacji:
    Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Electroporation*/methods
    Ablation Techniques/*methods
    Neoplasm Recurrence, Local/*therapy
    Prostate/*pathology
    Prostatic Neoplasms/*therapy
    Aged ; Feasibility Studies ; Humans ; Male ; Middle Aged ; Patient Safety ; Prospective Studies ; Quality of Life ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Reduced sensitivity of multiparametric MRI for clinically significant prostate cancer in men under the age of 50
    Autorzy:
    Gielchinsky I
    Scheltema MJ
    Cusick T
    Chang J
    Shnier R
    Moses D
    Delprado W
    Nguyen Q
    Yuen C
    Haynes A
    Stricker PD
    Pokaż więcej
    Temat:
    mpMRI
    prostate cancer
    young
    sensitivity
    Diseases of the genitourinary system. Urology
    RC870-923
    Źródło:
    Research and Reports in Urology, Vol Volume 10, Pp 145-150 (2018)
    Opis pliku:
    electronic resource
    Relacje:
    https://www.dovepress.com/reduced-sensitivity-of-multiparametric-mri-for-clinically-significant--peer-reviewed-article-RRU; https://doaj.org/toc/2253-2447
    Dostęp URL:
    https://doaj.org/article/b4ec74adc1404b349a97e434a01ce1bf  Link otwiera się w nowym oknie
    Czasopismo naukowe
    Szczegóły
    Tytuł:
    Prostate cancer in 432 men aged <50 years in the prostate-specific antigen era: a new outlook.
    Autorzy:
    Gielchinsky I; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
    Chang J; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
    Cusick T; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
    Delprado W; Douglass Hanly Moir Pathology, Macquarie Park, NSW, Australia.; School of Medicine, University of New South Wales, Kensington, NSW, Australia.
    Nguyen Q; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
    Yuen C; School of Medicine, University of New South Wales, Kensington, NSW, Australia.; St Vincent's Clinic, Sydney, NSW, Australia.
    Savdie R; School of Medicine, University of New South Wales, Kensington, NSW, Australia.; St Vincent's Clinic, Sydney, NSW, Australia.
    Böhm M; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
    Haynes AM; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
    Scheltema MJ; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
    Stricker PD; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; School of Medicine, University of New South Wales, Kensington, NSW, Australia.; St Vincent's Clinic, Sydney, NSW, Australia.
    Pokaż więcej
    Źródło:
    BJU international [BJU Int] 2018 Nov; Vol. 122 Suppl 5, pp. 35-41. Date of Electronic Publication: 2018 Nov 08.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Prostatectomy*
    Watchful Waiting*
    Prostatic Neoplasms/*pathology
    Prostatic Neoplasms/*therapy
    Disease-Free Survival ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Lymphatic Metastasis ; Male ; Middle Aged ; Neoplasm Staging ; Neoplasm, Residual ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms/blood ; Retrospective Studies ; Risk Assessment/methods ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Diagnostic accuracy of Ga-PSMA PET to mpMRI.
    Autorzy:
    Scheltema MJ; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Amsterdam UMC, Department of Urology, Amsterdam, The Netherlands.
    Chang JI; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
    Stricker PD; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
    van Leeuwen PJ; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Antoni van Leeuwenhoek Nederlands Kanker Instituut, Amsterdam, The Netherlands.
    Nguyen QA; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
    Ho B; St Vincent's Hospital Nuclear Medicine and PET Department, Darlinghurst, NSW, Australia.
    Delprado W; Douglass Hanly Moir Pathology, Macquarie Park, NSW, Australia.
    Lee J; St Vincent's Hospital Nuclear Medicine and PET Department, Darlinghurst, NSW, Australia.
    Thompson JE; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
    Cusick T; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.
    Spriensma AS; Amsterdam UMC, Department of Urology, Amsterdam, The Netherlands.
    Siriwardana AR; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.
    Yuen C; St Vincent's Clinic, Darlinghurst, NSW, Australia.
    Kooner R; St Vincent's Clinic, Darlinghurst, NSW, Australia.
    Hruby G; Genesis Cancer Care, St Vincent's Hospital, Darlinghurst, NSW, Australia.
    O'Neill G; St Vincent's Clinic, Darlinghurst, NSW, Australia.
    Emmett L; Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St Vincent's Hospital Nuclear Medicine and PET Department, Darlinghurst, NSW, Australia.
    Pokaż więcej
    Źródło:
    BJU international [BJU Int] 2019 Nov; Vol. 124 Suppl 1, pp. 42-49. Date of Electronic Publication: 2019 Jul 09.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Multiparametric Magnetic Resonance Imaging*
    Positron Emission Tomography Computed Tomography*
    Prostatectomy*
    Gallium Radioisotopes/*pharmacology
    Prostate/*pathology
    Prostatic Neoplasms/*pathology
    Radiopharmaceuticals/*pharmacology
    Aged ; Dimensional Measurement Accuracy ; Health Care Surveys ; Humans ; Male ; Middle Aged ; Prostate/diagnostic imaging ; Prostate-Specific Antigen/analysis ; Prostatic Neoplasms/diagnostic imaging ; ROC Curve ; Reproducibility of Results ; Sensitivity and Specificity
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment.
    Autorzy:
    Blazevski A; St. Vincent's Prostate Cancer Centre, Darlinghurst, New South Wales, Australia.; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
    Scheltema MJ; St. Vincent's Prostate Cancer Centre, Darlinghurst, New South Wales, Australia.; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia.; Department of Urology, Amsterdam UMC, Amsterdam, The Netherlands.
    Amin A; St. Vincent's Prostate Cancer Centre, Darlinghurst, New South Wales, Australia.; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia.
    Thompson JE; St. Vincent's Prostate Cancer Centre, Darlinghurst, New South Wales, Australia.; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
    Lawrentschuk N; EJ Whitten Prostate Cancer Research Centre at Epworth Healthcare, Melbourne, Victoria, Australia.; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.; Department of Surgery, Olivia Newton-John Cancer Centre, Austin Hospital, University of Melbourne, Melbourne, Victoria, Australia.
    Stricker PD; St. Vincent's Prostate Cancer Centre, Darlinghurst, New South Wales, Australia.; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia.; St. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
    Pokaż więcej
    Źródło:
    BJU international [BJU Int] 2020 Mar; Vol. 125 (3), pp. 369-378. Date of Electronic Publication: 2019 Dec 05.
    Typ publikacji:
    Journal Article; Review
    MeSH Terms:
    Electroporation*
    Ablation Techniques/*methods
    Prostatic Neoplasms/*surgery
    Biomedical Research ; Forecasting ; Humans ; Male
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
    Autorzy:
    Amin A; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.; St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia.
    Blazevski A; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.; St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia.
    Thompson J; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.; St George Clinical School, University of New South Wales, Sydney, NSW, Australia.
    Scheltema MJ; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.; Department of Urology, UMC, Amsterdam, The Netherlands.
    Hofman MS; Centre for Molecular Imaging, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Vic., Australia.
    Murphy D; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Vic., Australia.; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.
    Lawrentschuk N; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Vic., Australia.; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.; Department of Surgery, Austin Health, The University of Melbourne, Parkville, Vic., Australia.; Olivia Newton-John Cancer and Wellness Centre, Austin Health, Heidelberg, Vic., Australia.
    Sathianathen N; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.
    Kapoor J; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.
    Woo HH; Sydney Adventist Hospital Clinical School, University of Sydney, Wahroonga, NSW, Australia.; Department of Uro-Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia.
    Chalasani V; University of Sydney, Sydney, NSW, Australia.
    Rasiah K; Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.; Department of Urology, Royal North Shore Private Hospital, St Leonards, NSW, Australia.
    van Leeuwen PJ; Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
    Tang R; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.
    Cusick T; Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
    Stricker P; St Vincent's Prostate Cancer Centre, Darlinghurst, NSW, Australia.; Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.; St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia.
    Emmett L; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.; Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.; St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia.
    Pokaż więcej
    Źródło:
    BJU international [BJU Int] 2020 Apr; Vol. 125 (4), pp. 515-524. Date of Electronic Publication: 2020 Feb 12.
    Typ publikacji:
    Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antigens, Surface*
    Gallium Radioisotopes*
    Glutamate Carboxypeptidase II*
    Multiparametric Magnetic Resonance Imaging*
    Positron Emission Tomography Computed Tomography*
    Prostatic Neoplasms/*diagnostic imaging
    Cross-Sectional Studies/methods ; Humans ; Male ; Multicenter Studies as Topic/methods ; Prospective Studies
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Outcomes of salvage radical prostatectomy after initial irreversible electroporation treatment for recurrent prostate cancer.
    Autorzy:
    van Riel LAMJG; Department of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
    Geboers B; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St. Vincent's Prostate Cancer Research Centre, Sydney, NSW, Australia.
    Kabaktepe E; Department of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
    Blazevski A; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St. Vincent's Prostate Cancer Research Centre, Sydney, NSW, Australia.
    Reesink DJ; Department of Urology, St. Antonius Hospital, Nieuwegein, The Netherlands.
    Stijns P; St. Vincent's Prostate Cancer Research Centre, Sydney, NSW, Australia.
    Stricker PD; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; Department of Urology, St. Antonius Hospital, Nieuwegein, The Netherlands.
    Casanova J; Department of Urology, Instituto Valenciano de Oncologia, València, Spain.
    Dominguez-Escrig JL; Department of Urology, Instituto Valenciano de Oncologia, València, Spain.
    de Reijke TM; Department of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
    Scheltema MJ; Department of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.; Garvan Institute of Medical Research, Kinghorn Cancer Centre, Darlinghurst, NSW, Australia.; St. Vincent's Prostate Cancer Research Centre, Sydney, NSW, Australia.
    Oddens JR; Department of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
    Pokaż więcej
    Źródło:
    BJU international [BJU Int] 2022 Nov; Vol. 130 (5), pp. 611-618. Date of Electronic Publication: 2022 May 13.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Erectile Dysfunction*/etiology
    Prostatic Neoplasms*/surgery
    Prostatic Neoplasms*/pathology
    Male ; Humans ; Middle Aged ; Prostate-Specific Antigen ; Retrospective Studies ; Quality of Life ; Neoplasm Recurrence, Local/therapy ; Treatment Outcome ; Prostatectomy/adverse effects ; Prostatectomy/methods ; Salvage Therapy/methods ; Electroporation/methods
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Guidelines of guidelines: focal therapy for prostate cancer, is it time for consensus?
    Autorzy:
    Ong S; EJ Whitten Foundation Prostate Cancer Research Centre, Epworth HealthCare, Melbourne, Vic., Australia.; Department of Surgery, University of Melbourne, Melbourne, Vic., Australia.
    Chen K; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.; Department of Urology, Singapore General Hospital, Singapore City, Singapore.
    Grummet J; Department of Surgery, Central Clinical School, Monash University, Melbourne, Vic., Australia.
    Yaxley J; The University of Queensland, School of Medicine, Brisbane, QLD, Australia.; Wesley Urology Clinic, Wesley Hospital, Brisbane, QLD, Australia.; Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
    Scheltema MJ; St. Vincent's Prostate Cancer Research Centre, Darlinghurst, NSW, Australia.; Department of Urology, St Vincents Hospital and Campus, Sydney, NSW, Australia.
    Stricker P; St. Vincent's Prostate Cancer Research Centre, Darlinghurst, NSW, Australia.; Department of Urology, St Vincents Hospital and Campus, Sydney, NSW, Australia.; Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
    Tay KJ; Department of Urology, Singapore General Hospital, Singapore City, Singapore.
    Lawrentschuk N; EJ Whitten Foundation Prostate Cancer Research Centre, Epworth HealthCare, Melbourne, Vic., Australia.; Department of Surgery, University of Melbourne, Melbourne, Vic., Australia.; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Vic., Australia.; Department of Urology, Royal Melbourne Hospital, Melbourne, Vic., Australia.
    Pokaż więcej
    Źródło:
    BJU international [BJU Int] 2023 Jan; Vol. 131 (1), pp. 20-31. Date of Electronic Publication: 2022 Sep 27.
    Typ publikacji:
    Journal Article; Review
    MeSH Terms:
    Prostatic Neoplasms*/therapy
    Urology*
    Male ; Humans ; United States ; Aged
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
      Wyświetlanie 1-10 z 10

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies